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Abstract
Variability in blood pressure predicts cardiovascular disease in young- and middle-aged subjects, but relevant data for older
individuals are sparse. We analysed data from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study of
5804 participants aged 70–82 years with a history of, or risk factors for cardiovascular disease. Visit-to-visit variability in
blood pressure (standard deviation) was determined using a minimum of five measurements over 1 year; an inception
cohort of 4819 subjects had subsequent in-trial 3 years follow-up; longer-term follow-up (mean 7.1 years) was available for
1808 subjects. Higher systolic blood pressure variability independently predicted long-term follow-up vascular and total
mortality (hazard ratio per 5 mmHg increase in standard deviation of systolic blood pressure = 1.2, 95% confidence interval
1.1–1.4; hazard ratio 1.1, 95% confidence interval 1.1–1.2, respectively). Variability in diastolic blood pressure associated with
increased risk for coronary events (hazard ratio 1.5, 95% confidence interval 1.2–1.8 for each 5 mmHg increase), heart failure
hospitalisation (hazard ratio 1.4, 95% confidence interval 1.1–1.8) and vascular (hazard ratio 1.4, 95% confidence interval
1.1–1.7) and total mortality (hazard ratio 1.3, 95% confidence interval 1.1–1.5), all in long-term follow-up. Pulse pressure
variability was associated with increased stroke risk (hazard ratio 1.2, 95% confidence interval 1.0–1.4 for each 5 mmHg
increase), vascular mortality (hazard ratio 1.2, 95% confidence interval 1.0–1.3) and total mortality (hazard ratio 1.1, 95%
confidence interval 1.0–1.2), all in long-term follow-up. All associations were independent of respective mean blood
pressure levels, age, gender, in-trial treatment group (pravastatin or placebo) and prior vascular disease and cardiovascular
disease risk factors. Our observations suggest variability in diastolic blood pressure is more strongly associated with vascular
or total mortality than is systolic pressure variability in older high-risk subjects.
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Introduction
In daily practice and all major clinical guidelines [1–5], ‘usual’
or average blood pressure is considered to be the key or most
important measure determining risk of cardiovascular disease
(CVD); reductions in average blood pressure are generally thought
to account for the benefits of antihypertensive drugs [1–9].
However, recently Rothwell et al. [10] has questioned the usual
blood-pressure hypothesis, suggesting that visit-to-visit variability
in blood pressure (assessed across multiple visits) may have an
important additional role in increasing risk of vascular events, and
in particular stroke. Visit-to-visit variability in blood pressure is
increased in cohorts at high risk of stroke [11,12]. A secondary
analysis of several randomised controlled trials found that visit-to-
visit variability in systolic blood pressure and episodic hypertension
were strong predictors of stroke, independent of mean systolic
blood pressure [13]. In addition the adverse effects of variable
blood pressure may stretch beyond stroke. In a population-based
study of US adults, higher levels of visit-to-visit variability in
systolic blood pressure were associated with increased all-cause
mortality [14].
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However the risks associated with visit-to-visit variability of
blood pressure in older age are less clear; some investigators have
suggested such associations with visit-to-variability in systolic blood
pressure may decrease with advancing age [13]. Therefore, we
aimed to establish whether visit-to-visit variability in blood
pressure in older patients is associated with increased risk of
incident CVD. We performed an analysis of the PROspective
Study of Pravastatin in the Elderly at Risk (PROSPER) cohort
[15].
Methods
Study Design
Details of the design and outcome of PROSPER have been
published elsewhere [15–17]. Between December 1997 and May
1999 a total of 5804 individuals were screened and enrolled in
Scotland, Ireland and the Netherlands. Men and women aged 70–
82 years were recruited if they had either pre-existing vascular
disease (coronary, cerebral, or peripheral) or raised risk of such
disease because of smoking, hypertension or diabetes. Plasma total
cholesterol was required to be 4.0–9.0 mmol/L and triglyceride
concentrations #6.0 mmol/L. Individuals with poor cognitive
function (Mini-Mental State Examination score ,24 points) were
Figure 1. Flow chart.
doi:10.1371/journal.pone.0052438.g001
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excluded. The level of blood pressure was not part of the inclusion
or exclusion criteria. The institutional ethics review boards of all
centres approved the protocol and all participants gave written
informed consent. The protocol adhered to the principles of the
Declaration of Helsinki.
Blood Pressure Measurements
Sitting blood pressure was measured once at baseline and at
follow-up visits every three months during the randomised phase
of the trial (mean follow-up 3.2 years) with a fully automatic
electronic sphygmomanometer (Omron M4H) by trained research
nurses.
Outcomes and Follow-up
The outcomes for this study were incidence of cardiovascular
events, including definite or suspected death from coronary heart
disease or non-fatal myocardial infarction (CHD/MI), fatal or
non-fatal stroke, heart failure hospitalisation, vascular mortality
and total mortality.
All in-trial endpoints were assessed by the PROSPER
Endpoints Committee, which was blinded to study medication.
For this study the in-trial outcomes occurring over a maximum
of 3 years (mean 2.3 years), following one year of blood pressure
observations (i.e. five blood pressure measurements) were
analysed. This follow-up was considered ‘short-term’.
Routine health data on morbidity and mortality for the
Scottish sub-group (including post-trial follow-up) were obtained
from the Information Services Division, a division of National
Services Scotland, part of National Health Service Scotland.
The data obtained included the Scottish Morbidity Records
(SMR) - SMR00 outpatient attendances; SMR01 general acute
inpatient and day case discharges; SMR04 psychiatric admis-
sions, residents and discharges; SMR06 cancer registrations, and
General Register Office for Scotland death registrations. The
outcomes for the Scottish sub-group were followed up over a
maximum of 9.3 years (mean 7.1), following two years of blood
pressure observations (with nine blood pressure measurements).
This was considered the ‘long-term follow-up’.
Statistical Analysis
Baseline summary characteristics are reported as means with
standard deviations (SD) for continuous variables and as numbers
with percentage (%) for categorical variables. Variability of blood
pressure was quantified using the standard deviation (SD) and the
coefficient of variation (SD/mean; CV). The results for SD and
CV were qualitatively the same; therefore the results for SD are
presented. F-tests were used to test the difference in blood pressure
variability between participants receiving pravastatin and those
receiving placebo. The association of visit-to-visit variability in
blood pressure in relation to the different endpoints was assessed
separately for short- and long-term follow-up, the latter restricted
to the Scottish sub-cohort. For short-term follow-up blood pressure
variability was calculated from measurements made at visits 1 to 5
(0–12 months). In the Scottish sub-cohort which, in addition, has
Table 1. Baseline characteristics of participants with a short-term and long-term follow-up.
Follow-up
Short-term (whole cohort) (n = 4819)
Long-term (Scottish sub-cohort)
(n = 1808)
Continuous variates (mean, SD)
Age (years) 75.2 (3.3) 75.2 (3.4)
Systolic blood pressure (mmHg) 154.7 (21.6) 153.7 (20.8)
Diastolic blood pressure (mmHg) 83.9 (11.4) 82.9 (10.8)
Pulse pressure (mmHg) 70.8 (18.1) 70.9 (17.7)
Body mass index (kg/m2) 26.9 (4.2) 26.8 (4.1)
Alcohol (units per week)* 5.3 (9.4) 4.6 (8.2)
Total cholesterol (mmol/L) 5.7 (0.9) 5.7 (1.0)
Low-density lipoprotein cholesterol (mmol/L) 3.8 (0.8) 3.8 (0.8)
High-density lipoprotein cholesterol (mmol/L) 1.3 (0.4) 1.3 (0.4)
Triglycerides (mmol/L) 1.5 (0.7) 1.6 (0.7)
Mini-Mental State Examination (pts) 28.1 (1.5) 28.3 (1.4)
Barthel index (pts) 13.7 (1.0) 13.8 (0.8)
Instrumental activities of daily-living (pts) 19.8 (0.7) 19.8 (0.6)
Categorical variates (n, %)
Men 2339 (48.5) 876 (48.5)
Current smoker 1262 (26.2) 472 (26.1)
History of diabetes mellitus 492 (10.2) 144 (8.0)
History of hypertension 3016 (62.6) 1077 (59.6)
History of cardiovascular disease{ 2086 (43.3) 865 (47.8)
SD Standard deviation.
*1 unit = 60 ml distilled spirits, 170 ml wine or 300 ml beer.
{Any of stable angina, intermittent claudication, stroke, transient ischemic attack, myocardial infarction, peripheral arterial disease surgery, or amputation for vascular
disease more than 6 months before study entry.
doi:10.1371/journal.pone.0052438.t001
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longer-term follow-up, blood pressure variability was calculated
from measurements made from visit 1 to 9 (0–24 months).
Participants who had a CVD event during the blood pressure
variability measurement period (0–12 months for short-term
follow-up and 0–24 months for long-term follow-up) were
excluded from relevant analysis. Participants with one or more
missing blood pressure measurements, including those who died
during the blood pressure variability measurement period, were
excluded from the analyses. The agreement in blood pressure
variability was assessed for the short-term inception cohort by
analysing the Spearman Rank Correlation between the first three
blood pressure measurements and the last two measurements. For
the long-term Scottish sub-cohort, agreement in blood pressure
variability was assessed by analysing the Spearman Rank
Correlation between the first five blood pressure measurements
and the last four measurements.
The associations between measures of blood pressure variability
and time to occurrence of clinical outcomes were assessed using
Cox proportional hazards models. Measures of blood pressure
variability used were standard deviations and these were split into
quarters of their distributions and hazard ratios (HRs) and
corresponding 95% confidence intervals were calculated in
relation to the lowest quarter of SD (referent); homogeneity across
the quartiles was assessed using a general test of heterogeneity.
Analyses were adjusted for country (short-term analyses only),
randomized treatment group (pravastatin or placebo) and the
respective mean blood pressure measure during the period blood
pressure variability was assessed (mean systolic blood pressure for
systolic blood pressure variability; mean diastolic blood pressure
for diastolic blood pressure variability and mean pulse pressure for
pulse pressure variability) (Model 1). A second model (Model 2)
included additional adjustment for age, gender, smoking status,
and prior histories of diabetes, hypertension, cardiovascular
disease, cerebrovascular disease or peripheral vascular disease, as
well as body mass index (BMI), high density lipoprotein cholesterol
(HDL) and low density lipoprotein cholesterol (LDL). The results
for Models 1 and 2 were qualitatively the same; therefore the
results for Model 2 are presented in the main tables.
We performed a number of sensitivity analyses, including using
continuous values of the blood pressure variability measurements
to evaluate the influence of the splitting the blood pressure
variability measurements by quartiles. In this case continuous
measures of variability of blood pressure were reported as HRs per
5 mmHg increase in SD of systolic and diastolic blood pressure
and pulse pressure. HRs for one SD difference in baseline blood
pressure, mean blood pressure and blood pressure variability, for
systolic and diastolic blood pressure and pulse pressure were
calculated. Further subgroup analyses were conducted for gender,
the use of antihypertensive medication at baseline, baseline blood
pressure above and below the median and for patients with/
without a history of a stroke or transient ischaemic attack.
Table 2. Hazard Ratio’s for the endpoints associated with quartiles of the standard deviation (SD) of systolic blood pressure.
Short-term follow-up (n =4819)
Quartile of SD of systolic blood pressure, range in mmHg
Outcomes
Group 1
(n =1139)
#9 Group 2 (n=1194) .9–12.5 Group 3 (n =1266) .12.52#17 Group 4 (n=1220) .17
P for
heterogeneity
Coronary events (n = 407) 1 (ref) 0.8 (0.6–1.1) 1.0 (0.7–1.3) 1.0 (0.8–1.3) 0.563
Fatal/non-fatal stroke
(n = 158)
1 (ref) 1.0 (0.6–1.6) 1.1 (0.7–1.8) 1.2 (0.8–1.9) 0.764
Heart failure hospitalisation
(n = 144)
1 (ref) 0.5 (0.3–0.8) 0.8 (0.5–1.3) 1.0 (0.7–1.5) 0.019
Vascular mortality (n = 172) 1 (ref) 0.8 (0.5–1.2) 1.0 (0.6–1.5) 0.9 (0.6–1.3) 0.741
Total mortality (n = 330) 1 (ref) 1.0 (0.7–1.3) 1.1 (0.8–1.6) 1.0 (0.8–1.4) 0.676
Long-term follow-up (n=1808)
Quartile of SD of systolic blood pressure, range in mmHg
Group 1
(n =412)
#10.5
Group 2 (n=428) .10.52#13 Group 3 (n =471) .132#16.5 Group 4 (n=497) .16.5 P for
heterogeneity
Coronary events (n = 248) 1 (ref) 0.9 (0.6–1.3) 1.3 (0.9–1.9) 1.2 (0.8–1.7) 0.155
Fatal/non-fatal stroke
(n = 245)
1 (ref) 1.0 (0.7–1.5) 1.3 (0.9–2.0) 1.3 (0.9–1.8) 0.329
Heart failure hospitalisation
(n = 216)
1 (ref) 0.8 (0.5–1.3) 1.4 (1.0–2.1) 1.2 (0.8–1.8) 0.044
Vascular mortality (n = 315) 1 (ref) 1.1 (0.7–1.5) 1.5 (1.0–2.1) 1.6 (1.1–2.2) 0.016
Total mortality (n = 735) 1 (ref) 1.2 (1.0–1.5) 1.4 (1.1–1.7) 1.5 (1.2–1.8) 0.006
Data are presented as Hazard Ratios and 95% Confidence Intervals.
Adjustment for randomized treatment, country (short-term follow-up only), mean systolic blood pressure, age, gender, current smoker, histories of diabetes,
hypertension, cardiovascular disease, cerebrovascular disease & peripheral vascular disease, body mass index, high-density lipoprotein and low-density lipoprotein.
doi:10.1371/journal.pone.0052438.t002
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Results
Of the initial cohort of 5804 PROSPER participants, 5054 were
alive and had a full blood pressure profile up to 12 months (five
measurements); 235 of these participants were excluded from
analyses as having had a CVD event during this period, giving
4819 participants as an inception cohort to be included in the
short-term (in trial) follow-up analyses (Figure 1). For the long-
term follow-up (including post-trial) analyses only the Scottish sub-
cohort was eligible (n = 2520); 625 of these participants were
excluded because they did not have a full blood pressure profile
(up to two years, nine measurements); an additional 87 of these
participants were excluded as they had a CVD event during this
period, giving 1808 Scottish participants to be included in the
inception cohort for the long-term follow-up analyses (Figure 1).
Table 1 presents the baseline characteristics for the participants
in the short- and long-term follow-up. Of the 4819 participants in
the short-term follow-up 2339 (48.5%) were men, the mean age
was 75.2 years (SD 3.3) and 2086 (43.3%) had a history of
cardiovascular disease. Of the 1808 participants in the long-term
follow-up 876 (48.5%) were men, the mean age was 75.2 years (SD
3.4) and 865 (47.8%) had a history of cardiovascular disease.
We initially examined whether there was a difference in
variability in blood pressure between participants receiving
pravastatin and those receiving placebo. There was no significant
difference for short-term and long-term follow up, systolic and
diastolic blood pressure and pulse pressure (range of p-values
0.288–0.868); therefore, data from both groups were combined;
however all subsequent analyses were adjusted for randomized
treatment group because of the effect of the pravastatin on CVD
outcomes.
Blood pressure variability was reproducible for short-term and
long-term follow up, for systolic and diastolic blood pressure and
pulse pressure (p-value ,0.0001). The Spearman Rank Correla-
tion was higher when more blood pressure measurements were
added in the model.
Visit-to-visit Variability in Systolic Blood Pressure
Across the first five blood pressure measurements in the short-
term follow-up cohort the mean SD for variability of systolic blood
pressure was 13.6 mmHg. The mean SD for variability of systolic
blood pressure across the first nine blood pressure measurements
in the long-term follow-up cohort was 14.1 mmHg. Table 2
shows the results of the time-to-event analyses for the different
quartiles of SD of systolic blood pressure for all endpoints in the
short-term and long-term follow-up. In the long-term follow-up,
risk of vascular and total mortality increased across quartiles for
SD of systolic blood pressure in the fully adjusted model. SD of
systolic blood pressure per 5 unit change (mmHg) was associated
with coronary events (HR 1.1 (1.0–1.3); vascular mortality (HR
1.2, 95% CI 1.1–1.4) and total mortality (HR 1.1, 95% CI 1.1–
1.2) in the long-term follow-up. The predictive value of visit-to-
visit variability in systolic blood pressure was similar in all
subgroup analyses, including in participants with and without the
use of antihypertensive medication (data not shown).
Visit-to-visit Variability in Diastolic Blood Pressure
Across the first five measurements in the whole cohort the mean
SD of diastolic blood pressure was 7.3 mmHg. The mean SD of
diastolic blood pressure across the first nine measurements in the
Scottish sub-cohort was 7.4 mmHg. Table 3 shows the results of
the time-to-event analyses for the different quartiles of diastolic
Table 3. Hazard Ratio’s for the endpoints associated with quartiles of the standard deviation (SD) of diastolic blood pressure.
Short-term follow-up (n =4819)
Quartile of SD of diastolic blood pressure, range in mmHg
Outcomes
Group 1
(n =1127) #4.8
Group 2 (n =1157)
.4.82#6.5
Group 3
(n =1319)
.6.52#9
Group 4
(n =1216) .9 P for heterogeneity
Coronary events (n = 407) 1 (ref) 1.0 (0.8–1.4) 1.0 (0.8–1.4) 1.3 (1.0–1.8) 0.096
Fatal/non-fatal stroke (n = 158) 1 (ref) 0.8 (0.5–1.2) 1.0 (0.6–1.5) 0.6 (0.4–1.0) 0.211
Heart failure hospitalisation (n = 144) 1 (ref) 1.1 (0.7–1.9) 1.1 (0.7–1.9) 1.8 (1.1–3.0) 0.027
Vascular mortality (n = 172) 1 (ref) 0.8 (0.5–1.2) 1.3 (0.8–1.9) 1.3 (0.9–2.1) 0.056
Total mortality (n = 330) 1 (ref) 0.7 (0.5–1.0) 1.0 (0.8–1.4) 1.2 (0.9–1.6) 0.035
Long-term follow-up (n=1808)
Quartile of SD of diastolic blood pressure, range in mmHg
Group 1 (n =431)
#5.5
Group 2 (n =452)
.5.52#7
Group 3 (n =460)
.72#8.8
Group 4 (n =465)
.8.8
P for heterogeneity
Coronary events (n = 248) 1 (ref) 1.3 (0.9–1.9) 1.1 (0.7–1.6) 1.8 (1.3–2.6) 0.002
Fatal/non-fatal stroke (n = 245) 1 (ref) 1.1 (0.7–1.5) 1.0 (0.7–1.4) 1.3 (0.9–1.8) 0.470
Heart failure hospitalisation (n = 216) 1 (ref) 1.7 (1.1–2.5) 1.2 (0.8–1.8) 1.9 (1.3–2.8) 0.005
Vascular mortality (n = 315) 1 (ref) 1.3 (0.9–1.8) 1.1 (0.8–1.5) 1.6 (1.2–2.2) 0.020
Total mortality (n = 735) 1 (ref) 1.2 (0.9–1.5) 1.1 (0.9–1.3) 1.4 (1.1–1.7) 0.012
Data are presented as Hazard Ratios and 95% Confidence Intervals.
Adjustment for randomized treatment, country (short-term follow-up only), mean diastolic blood pressure, age, gender, current smoker, histories of diabetes,
hypertension, cardiovascular disease, cerebrovascular disease & peripheral vascular disease, body mass index, high-density lipoprotein and low-density lipoprotein.
doi:10.1371/journal.pone.0052438.t003
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blood pressure for all endpoints in the short-term and long-term
follow-up. In both short-term and long-term follow-up, high visit-
to-visit variability in diastolic blood pressure was associated with
increased risk of coronary events, heart failure hospitalisation and
vascular and total mortality. The HRs for heart failure hospital-
isation and coronary events in the long-term follow-up were 1.9
(95% CI 1.3–2.8) for the highest quarter versus lowest quarter of
SD of diastolic blood pressure and 1.8 (95% CI 1.3–2.6),
respectively in the fully adjusted model (Table 3). SD of diastolic
blood pressure per 5 unit change (mmHg) predicted coronary
events (HR 1.1, 95% CI 1.0–1.3) and heart failure hospitalisation
(HR 1.3, 95% CI 1.1–1.6) in the short-term follow-up. In the long-
term follow-up SD of diastolic blood pressure per 5 unit change
predicted coronary events (HR 1.5, 95% CI 1.2–1.8); heart failure
hospitalisation (HR 1.4, 95% CI 1.1–1.8); vascular mortality (HR
1.4, 95% CI 1.1–1.7) and total mortality (HR 1.3, 95% CI 1.1–
1.5).
Variability in diastolic blood pressure was more predictive for
coronary events in male participants (p for interaction= 0.008) and
for vascular mortality in male participants and participants with
systolic blood pressure below median (p for interaction= 0.043
and 0.028, respectively) in long-term follow-up.
Visit-to-visit Variability in Pulse Pressure
Across the first five measurements in the whole cohort the mean
SD of pulse pressure was 12.2 mmHg. Across the first nine
measurements in the Scottish sub-cohort the mean SD of pulse
pressure was 12.6 mmHg.
Table 4 shows the results of the time-to-event analyses for the
different quartiles of pulse pressure for all endpoints in the short-
term and long-term follow-up. In the short term follow-up, there
was no association between the SD of pulse pressure and the risk of
CVD events or mortality. In the long-term follow-up, high visit-to-
visit variability in pulse pressure was associated with increased risk
of stroke (HR for the highest quartile versus lowest quartile 1.6,
95% CI 1.1–2.4); vascular and total mortality (HR 1.3, 95% CI
1.0–1.8 and HR 1.3, 95% CI 1.1–1.6 respectively). When the
analyses were repeated for the continuous values of pulse pressure,
SD of pulse pressure per 5 unit change (mmHg) predicted stroke
(HR 1.2, 95% CI 1.0–1.4), vascular mortality (HR 1.2, 95% CI
1.0–1.3) and total mortality (HR 1.1, 95% CI 1.0–1.2) in the long-
term follow-up. Variability in pulse pressure was more predictive
for total mortality in participants with systolic blood pressure
below the median (p for interaction = 0.024).
Sensitivity Analyses
Table 5 shows the result of the analyses with one SD difference
in baseline, mean and variability in blood pressure in the long-
term Scottish cohort. One SD difference in baseline systolic and
diastolic blood pressure, but not pulse pressure, was associated
with an increased risk of stroke. One SD difference in mean
systolic and diastolic blood pressure and pulse pressure was
associated with an increased risk of stroke.
Table 4. Hazard Ratio’s for the endpoints associated with quartiles of the standard deviation (SD) of pulse pressure.
Short-term follow-up (n =4819)
Quartile of SD of pulse pressure, range in mmHg
Outcomes
Group 1
(n =1158)
#8
Group 2 (n =1149)
.82 #11
Group 3
(n =1231)
.112#15
Group 4
(n =1281) .15 P for heterogeneity
Coronary events (n = 407) 1 (ref) 0.8 (0.6–1.1) 0.9 (0.7–1.2) 0.8 (0.6–1.0) 0.287
Fatal/non-fatal stroke
(n = 158)
1 (ref) 0.9 (0.5–1.4) 0.9 (0.6–1.4) 1.2 (0.8–1.8) 0.526
Heart failure hospitalisation
(n = 144)
1 (ref) 1.3 (0.8–2.1) 1.0 (0.6–1.6) 1.1 (0.7–1.7) 0.575
Vascular mortality (n = 172) 1 (ref) 1.1 (0.7–1.7) 1.2 (0.8–1.8) 1.0 (0.6–1.5) 0.761
Total mortality (n = 330) 1 (ref) 1.3 (0.9–1.8) 1.3 (0.9–1.8) 1.2 (0.9–1.7) 0.415
Long-term follow-up (n=1808)
Quartile of SD of pulse pressure, range in mmHg
Group 1
(n =459)
#9.5
Group 2 (n =422)
.9.52#12
Group 3 (n =475)
.122#15
Group 4 (n =452) .15 P for heterogeneity
Coronary events (n = 248) 1 (ref) 0.9 (0.6–1.3) 1.0 (0.7–1.5) 1.1 (0.8–1.6) 0.727
Fatal/non-fatal stroke
(n = 245)
1 (ref) 1.1 (0.7–1.6) 1.5 (1.0–2.1) 1.6 (1.1–2.4) 0.024
Heart failure hospitalisation
(n = 216)
1 (ref) 0.8 (0.6–1.3) 1.1 (0.7–1.6) 1.2 (0.8–1.7) 0.357
Vascular mortality (n = 315) 1 (ref) 0.8 (0.6–1.2) 1.1 (0.8–1.6) 1.3 (1.0–1.8) 0.031
Total mortality (n = 735) 1 (ref) 1.1 (0.9–1.3) 1.2 (1.0–1.5) 1.3 (1.1–1.6) 0.068
Data are presented as Hazard Ratios and 95% Confidence Intervals.
Adjustment for randomized treatment, country (short-term follow-up only), mean pulse pressure, age, gender, current smoker, histories of diabetes, hypertension,
cardiovascular disease, cerebrovascular disease & peripheral vascular disease, body mass index, high-density lipoprotein and low-density lipoprotein.
doi:10.1371/journal.pone.0052438.t004
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One SD difference in variability in systolic and diastolic blood
pressure predicted an increased risk of vascular and total mortality,
but was not associated with an increased risk of stroke.
In the analyses with one SD difference in baseline, mean and
variability in blood pressure in the short-term follow-up cohort,
one SD difference in variability in diastolic blood pressure
predicted an increased risk in coronary events and heart failure
hospitalisation (HR 1.11, 95% CI 1.01–1.21 and 1.20, 95% CI
1.05–1.38, respectively), no other associations were found (data
not shown).
Discussion
This study shows that in older subjects visit-to-visit variability
in systolic blood pressure, diastolic blood pressure and pulse
pressure are associated with an increased long-term risk for
cardiovascular and total mortality. In addition variability in
diastolic blood pressure was predictive of coronary events and
heart failure hospitalisation; variability in systolic blood pressure
was predictive of heart failure hospitalisations. Variability in
pulse pressure (but not diastolic blood pressure or systolic blood
pressure) was somewhat associated with long-term stroke risk.
These associations were independent of respective mean blood
pressure values, the use of antihypertensive medication and
other risk factors.
The association of intra-individual variability in blood pressure
measurements with adverse clinical outcomes was first recognised
in the early 1990s [18–21]. Subsequent studies have investigated
the predictive value of visit-to-visit variability in blood pressure in
middle-aged people [19,22–25]. In contrast the present study
population consists of an older population (aged $70 years) with
Table 5. Hazard Ratio’s for the endpoints associated with one SD change in each blood pressure parameter (a–c) for the long-term
follow-up (n = 1808).
a. Systolic blood pressure.
Change of one standard deviation
Baseline SBP (SD=20.80 mmHg) Mean SBP (SD=15.53 mmHg) SD SBP (SD=4.88 mmHg)
Outcomes HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Coronary events 1.1 (0.9–1.2) 0.390 1.2 (1.0–1.32) 0.030 1.1 (1.0–1.3) 0.044
Fatal/non-fatal stroke 1.2 (1.0–1.3) 0.030 1.2 (1.1–1.4) 0.003 1.1 (1.0–1.3) 0.084
Heart failure hospitalisation 1.1 (0.9–1.2) 0.514 1.1 (0.9–1.2) 0.426 1.1 (1.0–1.3) 0.135
Vascular mortality 1.1 (1.0–1.2) 0.082 1.2 (1.1–1.3) 0.005 1.2 (1.1–1.4) .0.001
Total mortality 1.0 (1.0–1.1) 0.255 1.1 (1.0–1.2) 0.056 1.1 (1.1–1.2) .0.001
b. Diastolic blood pressure
Change of one standard deviation
Baseline DBP (SD=10.80 mmHg) Mean DBP (SD=7.13 mmHg) SD DBP (SD=3.66 mmHg)
Outcomes HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Coronary events 1.0 (0.9–1.1) 0.989 1.0 (0.9–1.1) 0.939 1.2 (1.1–1.4) 0.001
Fatal/non-fatal stroke 1.2 (1.0–1.3) 0.019 1.2 (1.1–1.4) 0.008 1.1 (1.0–1.2) 0.141
Heart failure hospitalisation 0.9 (0.8–1.0) 0.181 0.9 (0.8–1.0) 0.060 1.2 (1.0–1.3) 0.014
Vascular mortality 1.0 (0.9–1.2) 0.558 1.0 (1.0–1.2) 0.234 1.2 (1.1–1.3) 0.003
Total mortality 1.0 (1.0–1.1) 0.465 1.0 (1.0–1.1) 0.459 1.1 (1.1–1.2) .0.001
c. Pulse pressure
Change of one standard deviation
Baseline PP (SD=17.70 mmHg) Mean PP (SD=12.38 mmHg) SD PP (SD=4.33 mmHg)
Outcomes HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Coronary events 1.1 (0.9–1.2) 0.314 1.2 (1.1–1.4) 0.006 1.1 (1.0–1.2) 0.199
Fatal/non-fatal stroke 1.1 (0.9–1.2) 0.284 1.2 (1.0–1.3) 0.031 1.2 (1.0–1.3) 0.018
Heart failure hospitalisation 1.1 (1.0–1.3) 0.118 1.2 (1.0–1.3) 0.043 1.1 (0.9–1.2) 0.271
Vascular mortality 1.1 (1.0–1.2) 0.094 1.2 (1.1–1.3) 0.005 1.2 (1.0–1.3) 0.008
Total mortality 1.0 (1.0–1.1) 0.375 1.1 (1.0–1.2) 0.053 1.1 (1.0–1.2) 0.008
Data are presented as Hazard Ratios and 95% Confidence Intervals.
Adjustment for randomized treatment, country (short-term follow-up only), mean pulse pressure, age, gender, current smoker, histories of diabetes, hypertension,
cardiovascular disease, cerebrovascular disease & peripheral vascular disease, body mass index, high-density lipoprotein and low-density lipoprotein.
doi:10.1371/journal.pone.0052438.t005
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high risk of vascular events and deaths. Therefore, the present
study gives new insight into the clinical significance of blood
pressure variability with regard to morbidity and mortality in later
life. It has been suggested that the association between increased
variability in blood pressure and the risk of stroke is strongest in
younger age groups [10,13].
The reliability of blood pressure variability increased with the
number of measurements included, this is in line with previous
research in younger age groups [10,26]. It is possible that our
measures of blood pressure variability, although based on a
reasonably large number of individual measurements, may still
have underestimated the true magnitude of effect of variability on
clinical outcomes.
The association between visit-to-visit variability in systolic blood
pressure and increased total mortality found in older persons in
this present study is generally in line with previous research in
younger age-groups [13,14]. Visit-to-visit variability in systolic
blood pressure has also been claimed to be a predictor of stroke
[10,13,24,27] and coronary events [13,28], however in the present
study visit-to-visit variability in systolic blood pressure was not
associated with an increased risk of stroke or coronary events. In
contrast, sensitivity analyses in this present study showed that one
SD difference in baseline and mean systolic and diastolic blood
pressure was associated with an increased risk of stroke.
In our cohort, variability in pulse pressure was the only measure
that was associated with an increased risk of stroke, albeit modestly
so; systolic blood pressure variability may be a more powerful
predictor of stroke in younger cohorts; Rothwell et al. [13] found
an adjusted HR for stroke of 12.1 (95% CI 7.4–19.7; highest vs.
lowest decile) in a population aged 40–79 years. Such differences
between our study and other cohorts might be caused by higher
mean systolic blood pressure levels in our older cohort. However
there was no meaningful difference in average blood pressure
between our study and other relevant cohorts (e.g. mean systolic
blood pressure 150 mmHg in the UK-TIA and 164 mmHg at
baseline and 148 mmHg on treatment in the ASCOT-BPA [13]
compared to 154/155 mmHg in the present study).
In previous research, in predominantly younger populations
compared to the present study, no associations were present
between visit-to-visit variability in diastolic blood pressure and all-
cause mortality and CVD [13,14,28]. In contrast, our data suggest
that in older subjects diastolic blood pressure variability is more
strongly associated with coronary events and vascular or total
mortality than is systolic pressure variability, especially in male
subjects and those with systolic blood pressure below median. The
mechanisms for why diastolic blood pressure variability should be
more strongly associated with risk in elderly remain uncertain but
could speculatively include a bigger drop off in diastolic blood
pressure as marker of risk. In addition, it is also not clear why such
associations appear to be significantly stronger in men compared
to women. Clearly, our results suggest these issues merit further
study.
The present study reveals some differences in the association
between variability in the different blood pressure measurement
and outcomes and shows some differences with previous research.
One of the major differences between the present study and
previous research is the age of the participants. Although the
present study was not aimed to investigate etiological mechanisms
behind the observed associations, it is tempting to hypothesize that
the mechanisms involved in the association between variability in
blood pressure and stroke are different in younger and older
persons. In previous studies, greater variability in blood pressure
was related to older age and pulse pressure [13,14], which both
correlate with arterial stiffness. Arterial stiffness may play a role in
the found associations between variability in blood pressure and
CVD events. While variability increases with age, the association
with CVD events is not found to increase correspondingly with
similar analysis. The variability in systolic blood pressure found in
the present study was indeed higher than the variability in systolic
blood pressure found in younger populations (mean SD of systolic
blood pressure 14.1 mmHg vs. 7.7 mmHg [14]), while the
associated risk for total mortality was not higher. This could
indicate that there might be more competing mechanisms in older
persons than in younger persons.
This study has a number of strengths. Blood pressure was not
part of the inclusion or exclusion criteria for the PROSPER trial.
Therefore, people with the full range of baseline blood pressure
and variability in blood pressure were included. The estimation of
visit-to-visit variability should be reasonably reliable because of the
frequency of measurements. The large sample size allowed us to
conduct several subgroup analyses and investigating different
outcomes. However a limitation of this study is that long-term
follow-up was not assessed in the total PROSPER trial population
and it was only available for the Scottish sub-cohort. Another
potential limitation is that the participants were randomized to an
intervention (pravastatin vs. placebo), however, we found no
difference in variability in blood pressure between randomized
groups and all analyses were adjusted for the randomized
treatment. Third, we had no data on the use of antihypertensive
medications during the follow-up after the randomized control
trial ended. PROSPER was not designed to assess the effect of
blood pressure on outcomes and the accuracy of measurement of
blood pressure was reduced. By not having the perfect blood
pressure measurement we may have underestimated the true effect
of variability in blood pressure on clinical outcomes.
The present study aimed only to establish whether there is an
association between of visit-to-visit variability in blood pressure
and adverse CVD outcomes in older patients; however if these
associations are causal the results may have implications in the
management and treatment of blood pressure in the older
population. Besides the aim of lowering the usual level of blood
pressure in hypertensive patients, it is possible that additional
benefit might be obtained from reducing variability in blood
pressure. In a recent meta-analysis it was suggested that the use of
calcium channel blockers and non-loop diuretics results in less
systolic blood pressure variability than the use of ACE inhibitors
and angiotensin 2 receptor antagonists. Calcium channel blockers
have shown to reduce visit-to-visit variability compared with
placebo [29]. However, currently it is not certain whether
differential effects of various antihypertensives on variability in
blood pressure will also lead to clinical gains.
In conclusion, in older subjects at risk of CVD events variability
in systolic blood pressure is predictive for the risk of heart failure
hospitalisations and cardiovascular and total mortality; variability
in diastolic blood pressure is predictive for the risk of coronary
events, and vascular and total mortality; variability in pulse
pressure is predictive of stroke.
Author Contributions
Conceived and designed the experiments: RKEP SL DJS IF JG WDR NS
CJP SPM AJMDC RGJW JWJ. Performed the experiments: RKEP SL
DJS IF JG WDR NS CJP SPM AJMDC RGJW JWJ. Analyzed the data:
RKEP SL DJS IF JG WDR NS CJP SPM AJMDC RGJW JWJ.
Contributed reagents/materials/analysis tools: RKEP SL DJS IF JG WDR
NS CJP SPM AJMDC RGJW JWJ. Wrote the paper: RKEP SL DJS IF JG
WDR NS CJP SPM AJMDC RGJW JWJ.
Blood Pressure Variability and Cardiovascular Risk
PLOS ONE | www.plosone.org 8 December 2012 | Volume 7 | Issue 12 | e52438
References
1. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, et al. (2005)
Recommendations for blood pressure measurement in humans and experimen-
tal animals: part 1: blood pressure measurement in humans: a statement for
professionals from the Subcommittee of Professional and Public Education of the
American Heart Association Council on High Blood Pressure Research.
Circulation 111: 697–716.
2. O’Brien E, Asmar R, Beilin L, Imai Y, Mancia G, et al. (2005) Practice
guidelines of the European Society of Hypertension for clinic, ambulatory and
self blood pressure measurement. J Hypertens 23: 697–701.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003)
Seventh report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–
1252.
4. Mancia G, De Backer G., Dominiczak A, Cifkova R, Fagard R, et al. (2007)
2007 Guidelines for the Management of Arterial Hypertension: The Task Force
for the Management of Arterial Hypertension of the European Society of
Hypertension (ESH) and of the European Society of Cardiology (ESC).
J Hypertens 25: 1105–1187.
5. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, et al. (2008) European
Society of Hypertension guidelines for blood pressure monitoring at home: a
summary report of the Second International Consensus Conference on Home
Blood Pressure Monitoring. J Hypertens 26: 1505–1526.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific
relevance of usual blood pressure to vascular mortality: a meta-analysis of
individual data for one million adults in 61 prospective studies. Lancet 360:
1903–1913.
7. Klungel OH, de Boer A, Paes AH, Nagelkerke NJ, Seidell JC, et al. (2000)
Estimating the prevalence of hypertension corrected for the effect of within-
person variability in blood pressure. J Clin Epidemiol 53: 1158–1163.
8. Marshall T (2004) When measurements are misleading: modelling the effects of
blood pressure misclassification in the English population. BMJ 328: 933.
9. Keenan K, Hayen A, Neal BC, Irwig L (2009) Long term monitoring in patients
receiving treatment to lower blood pressure: analysis of data from placebo
controlled randomised controlled trial. BMJ 338: b1492.
10. Rothwell PM (2010) Limitations of the usual blood-pressure hypothesis and
importance of variability, instability, and episodic hypertension. Lancet 375:
938–948.
11. Cuffe RL, Howard SC, Algra A, Warlow CP, Rothwell PM (2006) Medium-
term variability of blood pressure and potential underdiagnosis of hypertension
in patients with previous transient ischemic attack or minor stroke. Stroke 37:
2776–2783.
12. Howard SC, Rothwell PM (2003) Regression dilution of systolic and diastolic
blood pressure in patients with established cerebrovascular disease. J Clin
Epidemiol 56: 1084–1091.
13. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, et al. (2010)
Prognostic significance of visit-to-visit variability, maximum systolic blood
pressure, and episodic hypertension. Lancet 375: 895–905.
14. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, et al. (2011) The
relationship between visit-to-visit variability in systolic blood pressure and all-
cause mortality in the general population: findings from NHANES III, 1988 to
1994. Hypertension 57: 160–166.
15. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a
randomised controlled trial. Lancet 360: 1623–1630.
16. Ford I, Blauw GJ, Murphy MB, Shepherd J, Cobbe SM, et al. (2002) A
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening
Experience and Baseline Characteristics. Curr Control Trials Cardiovasc Med 3:
8.
17. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, et al. (1999) The
design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER).
PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at
Risk. Am J Cardiol 84: 1192–1197.
18. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, et al. (2000)
Prognostic significance of blood pressure and heart rate variabilities: the
Ohasama study. Hypertension 36: 901–906.
19. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, et al. (2003) Systolic
blood pressure variability as a risk factor for stroke and cardiovascular mortality
in the elderly hypertensive population. J Hypertens 21: 2251–2257.
20. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G (1993) Prognostic value of
24-hour blood pressure variability. J Hypertens 11: 1133–1137.
21. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G (1987) Relationship of
24-hour blood pressure mean and variability to severity of target-organ damage
in hypertension. J Hypertens 5: 93–98.
22. Tozawa M, Iseki K, Yoshi S, Fukiyama K (1999) Blood pressure variability as an
adverse prognostic risk factor in end-stage renal disease. Nephrol Dial
Transplant 14: 1976–1981.
23. Havlik RJ, Foley DJ, Sayer B, Masaki K, White L, et al. (2002) Variability in
midlife systolic blood pressure is related to late-life brain white matter lesions: the
Honolulu-Asia Aging study. Stroke 33: 26–30.
24. Hata Y, Kimura Y, Muratani H, Fukiyama K, Kawano Y, et al. (2000) Office
blood pressure variability as a predictor of brain infarction in elderly
hypertensive patients. Hypertens Res 23: 553–560.
25. Hata Y, Muratani H, Kimura Y, Fukiyama K, Kawano Y, et al. (2002) Office
blood pressure variability as a predictor of acute myocardial infarction in elderly
patients receiving antihypertensive therapy. J Hum Hypertens 16: 141–146.
26. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, et al. (2010)
Prognostic significance of visit-to-visit variability, maximum systolic blood
pressure, and episodic hypertension. Lancet 375: 895–905.
27. Geeganage C, Tracy M, England T, Sare G, Moulin T, et al. (2011)
Relationship between baseline blood pressure parameters (including mean
pressure, pulse pressure, and variability) and early outcome after stroke: data
from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke 42: 491–
493.
28. Grove JS, Reed DM, Yano K, Hwang LJ (1997) Variability in systolic blood
pressure–a risk factor for coronary heart disease? Am J Epidemiol 145: 771–776.
29. Webb AJ, Fischer U, Mehta Z, Rothwell PM (2010) Effects of antihypertensive-
drug class on interindividual variation in blood pressure and risk of stroke: a
systematic review and meta-analysis. Lancet 375: 906–915.
Blood Pressure Variability and Cardiovascular Risk
PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e52438
